Faculty, Staff and Student Publications
Publication Date
8-1-2022
Journal
CEN Case Reports
Abstract
Thrombotic microangiopathy (TMA) in a cancer patient is a common complication of either cancer itself or anticancer therapy. Incidence of TMA from anticancer therapy was found to be > 15%, since the introduction of anti-angiogenic drugs like anti-vascular endothelial growth factor agents. It is, however, important to not ignore other causes of TMA such as bacteria, viruses, antiplatelet drugs, hereditary complement mutations, and autoimmune disorders. We present such a diagnostic dilemma in our patient who was admitted with influenza and was found to have TMA on renal biopsy, while on proteasome inhibitor (PI) therapy. With this case, we would like to highlight the importance of understanding the true cause of TMA to avoid unwarranted long-term discontinuation of life saving anti-cancer drugs after TMA resolution.
Keywords
Antineoplastic Agents, Humans, Influenza, Human, Neoplasms, Proteasome Inhibitors, Thrombotic Microangiopathies, Thrombotic microangiopathy, Influenza virus, Proteasome inhibitor, Cancer chemotherapy-induced kidney injury
DOI
10.1007/s13730-021-00681-z
PMID
34997535
PMCID
PMC9343559
PubMedCentral® Posted Date
1-7-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes